A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging.
Latest Information Update: 14 Jan 2020
Price :
$35 *
At a glance
- Drugs Ranolazine (Primary)
- Indications Myocardial ischaemia
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jun 2012 Additional location [Italy] identified as reported by ClinicalTrials.gov.
- 21 Feb 2012 Additional trial locations (Israel, Singapore) added as reported by ClinicalTrials.gov.